Recent Advances in Tumor Targeting via EPR Effect for Cancer Treatment
Open accessThe DOI matches its Crossref record; 172 of the 172 references it cites were found in a registry or an index.
Abstract
Cancer causes the second-highest rate of death world-wide. A major shortcoming inherent in most of anticancer drugs is their lack of tumor selectivity. Nanodrugs for cancer therapy administered intravenously escape renal clearance, are unable to penetrate through tight endothelial junctions of normal blood vessels and remain at a high level in plasma. Over time, the concentration of nanodrugs builds up in tumors due to the EPR effect, reaching several times higher than that of plasma due to the lack of lymphatic drainage. This review will address in detail the progress and prospects of tumor-targeting via EPR effect for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 The two phenomena of extravasation and later diffusion and convection of the colloid in the extracellular matrix both result in enhanced permeation and retention of the nanoparticles [32].](https://figures.cochat.ai/paper-figures/887ab73c266443efbb3420cd636da176/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-1.jpg)
![Figure 2 Common strategies utilizing the EPR effect [109].](https://figures.cochat.ai/paper-figures/89ba4512a64543b1a593fb62b3bf1725/recent-advances-in-tumor-targeting-via-epr-effect-for-cancer-treatment-figure-2.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In clinical settings, one of the main challenges for the delivery of macromolecules and nanomedicine to the cancer site is due to the heterogeneity of the EPR effect in solid tumors [20].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have demonstrated that only 0.1 to 0.2% of the injected dose is efficient against tumor cells and exhibits significant anticancer effects [20,123,161].”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [20]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873 · cited 1×
“The rapid tumor growth and improper development of blood vessels in murine tumors result in a much leakier vasculature as compared to human tumors that can lead to misinterpretation of the EPR effect [78].”
BackgroundDoxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792 · cited 1×
“The liposomal doxorubicin extravasated and accumulated intact in tumors with a leaky vasculature [79].”
BackgroundNanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233 · cited 1×
“To date, the FDA has approved many other liposomal formulations such as DaunoXome®, which contains daunorubicin, and Marquibo®, which contains vincristine sulfate for cancer therapy [123] as well as other types of nanoparticle including polymeric micelles containing paclitaxel (Genexol® PM), micelles built with PEG an…”
BackgroundFactors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699 · cited 1×
“The physicochemical properties of any external material for therapeutic or diagnostic purposes are important in drug delivery as they impact the way the host defense mechanisms clear them from the systemic circulation [57,58].”
BackgroundLiposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180 · cited 3×
“They also depend on what stage the cancer is and the site it is located at [26,27,39].”
BackgroundNanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039 · cited 1×
“These nanoparticles with a size below 50 nm are mostly used for the detection of brain tumors [140].”
REJMAN, J., OBERLE, V., ZUHORN, I. S., & HOEKSTRA, D. (2004) · Biochemical Journal · doi:10.1042/bj20031253 · Cited by 2,864 · cited 1×
“and spleen, but large enough to avoid kidney clearance [7,8].”
BackgroundBertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Research works printed but not linked: 1
- Dellian, 2000, Vascular permeability in a human tumour xenograft: Molecular charge dependence, Br. J. Cancer, 82, 1513
Cited by
Items 501–600 of 657
Sharma, A., Modgil, M., Joshi, G., & Bisht, P. (2024) · Current Cancer Drug Targets · doi:10.2174/0115680096323618240911140624 · Cited by 1
Application of Nanocarrier Systems in Cancer Treatment
Reihani, N., Atrooz, O. M., Mozafari, M. R., & Taghavi, E. (2024) · Interdisciplinary cancer research · doi:10.1007/16833_2024_478 · Cited by 1
Reshetov, I. V., & Romanko, Y. S. (2023) · Голова и шея. · doi:10.25792/hn.2023.11.2.81-91 · Cited by 1
Nanoparticle-Mediated Treatment for Brain Tumours
Kanet, B., Patel, F., Chauhan, V., Modi, C. D., Rana, H., Udhwani, N. H., & Prajapati, B. G. (2025) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-80185-3_4 · Cited by 2
Polymeric Nanocarriers for Advanced Cancer Therapy: Current Developments and Future Prospects
Saraf, A., & Sharma, M. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815305906125010016 · Cited by 2
Folic acid–encapsulated silver nitroprusside nanoparticles for targeted therapy in ovarian cancer
Patel, A., Londhe, S., Tripathy, S., Nagchowdhury, P., & Patra, C. R. (2025) · Biomedical Materials · doi:10.1088/1748-605x/add2b9 · Cited by 1
“Larger nanoparticles have better retention in tumors, as they are less likely to diffuse back into circulation compared to smaller ones [80].”
Jha, M., Bhattacharya, S., Gupta, G. L., Prajapati, B. G., & Kapoor, D. U. (2025) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1177/10849785251381993 · Cited by 5
Rizzuti, B. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12101662 · Cited by 1
“A Special Issue on EPR effect-based targeted nanomedicine [11] was recently published in the Journal of Personalized Medicine and it includes, among other works, a detailed historical perspective [12], discussion of the significance of the EPR concept [13], and recent advances in its importance for cancer treatment [1…”
BackgroundSonosensitive emulsions for therapeutic applications
Thimonier, C. (2022) · theses.fr (ABES) · doi:10.70675/dcfc2200z6efez4756z8f04za773df8825f8 · Cited by 2
Statistical analysis of self-assessed quality of life in cancer clinical trials
Beacon, H. J. (2013) · PubMed Central · doi:10.17037/pubs.00682265
Inorganic Nanoparticles in Anti-angiogenic Cancer Therapy
Mukherjee, S., & Madamsetty, V. S. (2022) · Synthesis lectures on biomedical engineering · doi:10.1007/978-3-031-11284-3_5
Progress of Cancer Nano Medicine, Clinical Hurdles, and Opportunities
Tagde, P., Sharma, A., Goyal, K., & Jindal, S. (2022) · Springer eBooks · doi:10.1007/978-981-19-5558-7_3 · Cited by 1
Nano based Drug Delivery System for Cancer Therapy: A Next Generation Theranostics
Prabu, S. L. (2022) · Bioequivalence & Bioavailability International Journal · doi:10.23880/beba-16000178
Current progress in PLGA-based nanoparticles for treatment of cancer diseases
Karasu, İ., Akbaş, S., & Çapan, Y. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91215-0.00008-x
Different administration routes for nanovectors in cancer immunotherapy
Vaez, A., Amani, A. M., Salehi, M., Zarei‐Behjani, Z., Rezvani, A., Dourtaj, H., Hooshmand-Ardakani, A., & Arabpour, Z. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-18770-4.00013-5
Liposomes for drug delivery to cancer cells
Sofou, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15491-1.00020-1
Cancer Nanomedicines in the Clinic: Coming of Age
Zaheer, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-3545-7_15
Agarwal, M., Vincy, A., Sridevi, G., & Vankayala, R. (2024) · Chemistry - An Asian Journal · doi:10.1002/asia.202400658
Jain, B., Verma, D. K., Rawat, R. N., & Berdimurodov, E. T. (2024) · Current Pharmaceutical Design · doi:10.2174/0113816128317407240724065912
Takeshita, K., Nakagawa, Y., Yokoyama, E., Shinohara, N., Miura, K., Naka, S., Nishida, M., Yasukawa, K., Ohta, Y., Fang, J., et al. (2024) · Journal of drug targeting · doi:10.1080/1061186x.2024.2409886
“…effect because of differences in vascular permeability, the extracellular matrix, tumour cell density, hypoxia, and interstitial fluid pressure [4,10]. it is also recognised that blood vessels in human tumours are less leaky than those in animal models [9,11,12]. therefore, for the development…”
Commercialized nanomedicines until to date
Kainthan, R. K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22257-3.00015-5 · Cited by 1
Influence of Nanomedicine as a Smart Weapon for Multidrug Resistance in Cancer Therapy
Paikray, S. K., Sahoo, L., Tripathy, N. S., & Dilnawaz, F. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010336491241022094511
Theranostic liposome-mediated drug delivery for anticancer applications
Rani, V., & Prabhu, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22044-9.00010-3 · Cited by 1
Mellor, R. D. (2024) · Springer eBooks · doi:10.1007/978-3-031-59478-6_9
Application of Nanotechnology in the Diagnosis and Treatment of Brain Metastases
Schonfeld, E., Sunshine, J. C., Guss, Z. D., Pillai, J. J., Kendall, L., & Lim, M. K. (2024) · Springer eBooks · doi:10.1007/978-3-030-80662-0_25
Nanotechnology in Biomaterials: Revolutionizing Drug Delivery Systems
Raheem, A. (2024) · Premier Journal of Engineering · doi:10.70389/pje.100001
Lipid-based drug delivery for lungs cancer
Shaikh, M. S., Kurhade, R. R., Majeed, S. S. A., Sangshetti, J. N., & Faiyazuddin, M. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-22374-7.00009-8 · Cited by 1
Gold Nanoparticle-Based Photothermal Therapy in Breast Cancer: Innovations and Challenges
Takallu, S. (2024) · Materials chemistry horizons. · doi:10.61186/mch.2025.1073
Innovative Theranostics Strategies in the Fight Against Lung Cancer
Jain, A., Soni, S., Soni, V., & Kashaw, S. K. (2025) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575338753250228055700
New developments in the nanocarrier-based drug delivery system for the treatment of breast cancer
Yahyai, R. A., & Kalbani, J. A. (2025) · Asia-Pacific Journal of Pharmacotherapy & Toxicology · doi:10.32948/ajpt.2025.03.10 · Cited by 1
Anomalous tumor microenvironment: exploitable features for drug delivery
Raikwar, S., Vishwakarma, N., Rathee, S., Patil, U. K., & Jain, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29125-8.00001-6 · Cited by 2
Nanotechnology in Drug Delivery: From Bench to Bedside
Mankad, M. C., Anjaria, P. A., Vaghela, S., & Asediya, V. (2025) · Methods in pharmacology and toxicology · doi:10.1007/978-1-0716-4554-3_4
Trojan Horses: A Secret Route for Nanomedicines
Amin, Z., Nadeem, D., Shakil, H., Jatoi, M. A., Baloch, R., & Ali, R. (2025) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010388510250515105129 · Cited by 2
Proteins, peptides and its derivatives as ligand and applications in drug delivery
Triveni, T., Kaul, S., Nagaich, U., Mishra, D. K., Pandey, M., & Jain, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33366-8.00002-6
Fuloria, N. K., Fuloria, S., Sekar, M., Narain, K., & Kumar, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30120-9.00001-5
Zhang, Y., Fardous, J., Doi, R., Inoue, Y., Ikegami, Y., & Ijima, H. (2025) · Pharmaceutical Development and Technology · doi:10.1080/10837450.2025.2518564
“Literature on the EPR effect further reinforces the viewpoint that G/W achieves local accumulation in tumor tissues (Subhan et al. 2021).”
Bhattacharjee, A., Biswas, N. G., Bhattacharjee, A., Murugan, R., Swain, R. P., & Sahu, R. K. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815313260125010011
Current advances and future vision of drug delivery systems for cancer
Braccia, S., Ajayi, O. E., Palladino, S., Imbò, L. E., Bellavita, R., Falanga, A., Alfano, L., Giordano, A., & Galdiero, S. (2025) · Annals of Research in Oncology · doi:10.48286/aro.2025.106
NALLAMUTHU, M., & Subramanian, U. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i4.53942
Smart Nanocarriers for Targeted Drug Delivery in treatment of oral cancer
Khaksar, E. (2025) · Journal of Oral and Dental Health Nexus · doi:10.61838/kman.jodhn.2.3.5
Soliman, S. A., Ajji, Z., & Al-Laham, A. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103529
Antitumor Activity of Alexidine Dihydrochloride Nanocarriers in Renal Cell Carcinoma
Sultan, A., Zoabi, A., Morshin, A., Shalev, O., Lazarovici, P., & Margulis, K. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00651
Cationic nanoparticles for drug delivery targeting the brain
AlHoda, M., Daoud, R. M., Esther, A., & Greish, K. F. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26657-7.00008-8
Liu, Z., Sun, J., Wu, W., Jiao, T., Li, J., & Yu, Z. (2025) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2025.138393
Functional Nanohybrids for Solid Tumor Theranostics
Chavda, V. P., Koul, S., Vaghela, D. A., Bedse, A. P., & Patel, R. (2025) · Springer eBooks · doi:10.1007/978-981-95-0938-6_2
Tumor Microenvironment-Responsive Nanoplatforms for Triggering Drug Delivery
Melia, F., Udomjarumanee, P., Rogoyski, R., & Pranjol, M. Z. I. (2025) · Springer eBooks · doi:10.1007/978-3-032-00773-5_412
Treating venous malformations with nanomedicines
Tang, W., Kohane, D. S., & Cullion, K. (2025) · Nanomedicine · doi:10.1080/17435889.2025.2573627
Porous silicon–based nanocarriers for tumor targeting
Zafaryab, M., & Iftikhar, C. M. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24802-3.00005-6
Mesoporous silica-based nanocarriers in pulmonary drug delivery
Kumar, D., & Viswalingam, V. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24802-3.00010-x
Abbas, F., Rahman, M. S., Hasan, M., & Siraj, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-40431-3.00014-1
Polymer-based nanomaterials in photodynamic therapy
Kamal, S., Malik, S., Batool, F., Rehman, K., Ain, Q., Ihsan, A., Ullah, R., Bibi, I., & Akash, M. S. H. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-40431-3.00010-4
Role of polymeric nanodots in cancer diagnosis and treatment
Parihar, A., Yadav, K., Pal, S., Sharma, R., & Prajapati, B. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27511-1.00005-4
Kunjiappan, S., Murugesan, S., & Pavadai, P. (2026) · Journal of Polymers and the Environment · doi:10.1007/s10924-026-03820-8
Nanoemulsion and nanosuspension for prostate cancer management: A comparative perspective
Prajapati, V. D., Ferreir, J. L., Rana, P., Wagh, B., & Prajapati, B. G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33208-1.00011-1
Biofate and cellular interactions of liposomes
Rostamnezhad, M., Morad, H., Kargar, M., & Moein, N. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33548-8.00015-x
Liposomes mediated anticancer drug delivery approaches for treatment of skin cancer
Aktürk, Ö. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33548-8.01007-7
Man, S., Tao, J., Zhang, S., Shi, D., Ma, L., & Gao, W. (2025) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2025.139309
Tarkade nanoosakeste väljatöötamine eksperimentaalseks vähiraviks
Tobi, A. (2024) · DSpace repository (University of Tartu)
Thakur, A., & Jeswani, G. (2025) · De Gruyter eBooks · doi:10.1515/9783111593654-007
Current Advances in Drug Development, Design, and Strategies for Brain Tumors
Waghulde, S., Pawar, D., & Vaidhun, B. H. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898811716125010004
Rab, S. O., AlKhafaje, Z., Hussein, U. A.-R., Adel, Z., Alkadir, O. K. A., Aldulaimi, A., Saeed, S. M., Taher, W. M., Alwan, M., & Smerat, A. (2025) · Cardiovascular Toxicology · doi:10.1007/s12012-025-10078-4
“Leaky vasculature permits macromolecules and nanoparticles to escape into surrounding tumor stroma [ 72 ].”
Engineered nanoparticles for endocrine tumor targeting, current progress and future outlook
Aftab, M., Ahmed, Z., Ullah, M., Khan, S. U., Naeem, M., Khan, A. P., & Wahab, A. (2025) · Medical Oncology · doi:10.1007/s12032-025-03151-z
“The distribution of NPs to cancer cells can be hampered by a number of variables, such as increased collagen levels and macrophage absorption in the extracellular matrix, and decreased blood flow within tumor regions caused by overexpressing VEGFR2 [127].”
Kang, H. G., Mitra, S. A., Upton, B., Parmentier, J. H., Hovsepyran, A., Nagy, J. O., & Triche, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.06.697855
Fakudze, N., Chota, A., Abrahamse, H., & George, B. P. A. (2026) · Springer eBooks · doi:10.1007/978-981-95-3682-5_21
Chen, S., Zhang, T., Qu, L., Han, S., Sun, M., & Yang, X. (2026) · Advanced Functional Materials · doi:10.1002/adfm.202515201 · Cited by 1
Yasmeen, N., Kumar, V., Ali, M. G., & Rawas, H. O. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33347-7.00006-3
Mashreghi, M., Bazaz, M. R., & Jaafari, M. R. (2026) · Biotechnology Progress · doi:10.1002/btpr.70105
“25 Furthermore, as a result of complexation between ionizable lipids and negatively charged pDNA, the size of empty LNP decreased slightly after incorporation of the pDNA.”
Soltani, T., Karimian, M., Vaziri, H., Karimi, M., & Nejati, M. (2026) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2026.102455
“In addition, nanoemulsions can exploit the enhanced permeability and retention (EPR) effect to achieve targeted drug delivery [51].”
Wang, Y., Wu, P., Lou, S., Zhang, Y., Zhang, H., Liu, W., Yang, L., & Shen, R. (2026) · Journal of Rare Earths · doi:10.1016/j.jre.2026.02.013
Cruz, L. J. (2025) · JESTE Journal of Emerging and Sustainability Technologies for Engineering · doi:10.25057/31150829.1758
Epigenetic Targets of Polyphenolic Nanoparticles in Cancer: Current Insights
Tomar, M., Shringi, H., & Goyal, M. (2026) · Premier journal of science. · doi:10.70389/pjs.100259
Nankali, E., Kavaz, D., Shaabanzadeh, M., & Asina, N. (2026) · Journal of Biomaterials Science Polymer Edition · doi:10.1080/09205063.2026.2633191
ZnO-based nanocarriers for drug delivery applications
Nousi, A. (2026) · DSpace - NTUA (National Technical University of Athens) · doi:10.26240/heal.ntua.31404
New Approaches in Drug Delivery Systems for Brain Tumor Treatment (A Review)
Shekarian, K., Abdolmaleki, A., Nahumi, A., Asadi, A., & Ghanimi, H. A. (2026) · Cell and Tissue Biology · doi:10.1134/s1990519x26600018
Dispersion Technique May Change Structure and Bio-Oxidative Activity of Magnetic MOF Nanoparticles
Bondarenko, L. S., Dzeranov, A. A., Сергеевна, Т. Н., & Kydralieva, K. A. (2026) · Eurasian Journal of Chemistry · doi:10.31489/2959-0663/1-26-8
Kamal, R., Chauhan, A., Singh, T. G., Dhiman, S., & Awasthi, A. (2026) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2026.2648023 · Cited by 1
“In active targeting, ligand conjugation strategies, which involve the use of a ligand to the nanoparticle surface [49], play the main role, whereas the physicochemical properties of nanoparticles, for example, size and surface properties, help passive targeting through the EPR effect [50].”
Shaping Micelles, Targeting Cancer: The Power of Block Copolymer Architectures
Park, S., Patel, G. C., Padhan, B., Das, J., Raghava, R. B. T. S., & Patel, M. (2026) · Macromolecular Bioscience · doi:10.1002/mabi.70174
Advantage of cancer nanomedicine
Saied, S. A., Selim, M. T., & Salem, S. S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44579-8.00020-5
Targeted Nanotheranostics for Selective Drug Delivery in Cancer
Sharma, V. K., Yadav, P., Singh, S., & Shrivastav, D. (2026) · Springer eBooks · doi:10.1007/978-981-95-5589-5_8
Öztürk, P. (2024) · İYTE (İZMİR YÜKSEK TEKNOLOJİ ENSTİTÜSÜ)
PEGylated micelles for diagnostic and therapy against solid tumors
Hoang, S. (2023) · theses.fr (ABES) · doi:10.70675/09372216z79abz4abezad38z6ae6634e0c3f
Journaux, J. (2023) · theses.fr (ABES) · doi:10.70675/f881b446z9b1az4d24z89cbz2922c25af06e
PAMAM dendrimers as efficient drug nanocarriers of natural compounds in breast cancer therapeutics
Gulfishan, S., Alam, M. W., Pandey, P., Mujtaba, M. A., Verma, M., Lakhanpal, S., Rana, A. K., & Khan, F. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1809604
“The passive mechanism relies on the accumulation of PEGylated dendrimers in cancerous tissues, which is attributed to the permeability and retention effects (83).”
Keçeci, Y. Ö., Demirel, M., & Seller, Z. (2026) · ACS Omega · doi:10.1021/acsomega.5c10848
Wang, L., Gao, D., Chen, X., & Chen, Y. (2026) · Marine Drugs · doi:10.3390/md24050148
“Passive EPR-based strategies are simpler but fundamentally constrained by EPR heterogeneity across tumor types [164].”
Martins, M. G., de França, B. M., Jatobá, L. T., Horta, M. K. D. S., Silva, J. D., Valente-Rodrigues, C. L., García, F., dos Santos, C. M. S. D. F. F., Lopes, R. D. D. C., Pinto, J. C., et al. (2026) · ACS Applied Nano Materials · doi:10.1021/acsanm.6c00226
Sriwastava, A. M. S., Pratima, K., Singh, A. K., & Kumar, M. (2026) · Nanotechnology · doi:10.1088/1361-6528/ae6f1c
Local drug delivery for oral squamous cell carcinoma under oral cavity
Ruslin, M., Cao, J., Ullah, M., Palungan, J., Azizah, W., Ode, R. C. W., Mustofa, A. Z., Marlina, E., Uchida, S., Yoo, J., et al. (2026) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2026.115114
Waghmare, S., Palekar, R., Bramhe, P., Rarokar, N. R., & Khedekar, P. B. (2026) · Nano-Structures & Nano-Objects · doi:10.1016/j.nanoso.2026.101711
Nanotechnology and drug delivery: Fundamentals and applications
Purohit, A., Nema, P., Kumar, A., Kumar, N. D., Soni, V., & Kashaw, S. K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44119-6.00017-3
Nanoparticle-based delivery of corn silk extract for the treatment of CCl₄-induced hepatotoxicity
Farid, A., Badawi, A., Waheed, M., Ashraf, M., Amr, M., & Amin, A. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.152961
Somashekhar, B. G. K., Nagarajnaik, S., Thippeswamy, M., Gangiah, S., Ramesha, A. G., Hadapada, L., Sriramareddy, Y., & Madappan, D. (2026) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-026-10814-5
“Enzyme-responsive strat - egies use peptide or ester linkers which tumor-associated enzymes, specifically matrix metalloproteinases and phos - pholipases, can break down to produce localized activation and biomimetic responsiveness which resembles natural membrane remodeling activities [113].”
Danalache, B. A., Faye, M. T., Zgheib, A., & Annabi, B. (2026) · IntechOpen eBooks · doi:10.5772/intechopen.1016009
Nanocapsules as smart natural product drug delivery systems: recent advances and future directions
Asmara, A. P., Razack, S. A., Cheong, C. S. Y., Nisah, K., & Prasansuklab, A. (2026) · Nanoscale Horizons · doi:10.1039/d6nh00103c
Polypept(o)ide-based nanostructures for therapeutic and diagnostic application
Schäfer, G. (2026) · Leiden Repository (Leiden University) · doi:10.60602/1887-4304732
Metadata
- Authors
- Subhan, M. A., Yalamarty, S. S. K., Filipczak, N., Parveen, F., & Torchilin, V. P.
- Affiliations
- Shahjalal University of Science and Technology (BD)
- Northeastern University (US)
- Corresponding author
- Subhan, Md Abdus
- Torchilin, Vladimir P.
- ORCID
- Venue
- Journal of Personalized Medicine
- Publisher
- MDPI AG
- Published
- 2021-06-18
- Volume
- 11
- Issue
- 6
- Pages
- 571
- ISSN
- 2075-4426 (ISSN-L)
- PMC
- PMC8234032
- OpenAlex
- W3174294541
- Semantic Scholar
- 0e274cc5538c8ce64b42706c752e9cd357ce4ede
- Cited by
- 623
- References
- 172
- Citations by year
- 2026: 116 · 2025: 167 · 2024: 148 · 2023: 106 · 2022: 82 · 2021: 4
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Personalized Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Engineering › Biomedical Engineering › Ultrasound and Hyperthermia Applications
- Keywords
- enhanced permeability and retention effect, tumor targeting, cancer nanomedicine, nanotherapeutics, tumor selectivity, intravenous drug delivery, tumor microenvironment, lymphatic drainage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.